Substance / Medication

Ponatinib

Overview

Active Ingredient
ponatinib
RxNorm CUI
1364347

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
Efficacy of Ponatinib Versus Earlier Generation Tyrosine Kinase Inhibitors for Front-line Treatment of Newly Diagnosed Philadelphia-positive Acute Lymphoblastic Leukemia.
Jabbour Elias, DerSarkissian Maral, Duh Mei Sheng et al. · Clin Lymphoma Myeloma Leuk · 2018
PMID: 29519619Meta-Analysis
Response-Based Dosing for Ponatinib: Model-Based Analyses of the Dose-Ranging OPTIC Study.
Hanley Michael J, Diderichsen Paul, Rich Benjamin et al. · Clin Pharmacol Ther · 2023
PMID: 37219378RCT
Effects of food on the pharmacokinetics of ponatinib in healthy subjects.
Narasimhan N I, Dorer D J, Niland K et al. · J Clin Pharm Ther · 2013
PMID: 23888935RCTFull text (PMC)
Effects of ketoconazole on the pharmacokinetics of ponatinib in healthy subjects.
Narasimhan Narayana I, Dorer David J, Niland Katie et al. · J Clin Pharmacol · 2013
PMID: 23801357RCTFull text (PMC)
Ponatinib for CML patients in routine clinical practice: the PONDEROSA study.
Schenk Thomas, Fabisch Christian, Ernst Thomas et al. · Ann Hematol · 2026
PMID: 41535610ObservationalFull text (PMC)
One-year consolidation with Ponatinib 15 mg in chronic myeloid leukaemia on deep molecular response with Imatinib.
Pérez-Lamas Lucía, Manzanares Mario, Hernández Boluda Juan Carlos et al. · Ann Hematol · 2026
PMID: 41557074ObservationalFull text (PMC)

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Ponatinib (substance)
SNOMED CT
703796003
UMLS CUI
C2987417
RxNorm CUI
1364347

Clinical Data

This intervention maps to 1 entities in the Healos knowledge graph.

1
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.